Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

Objective To determine the ability of montelukast, a leukotriene receptor a ntagonist, to allow tapering of inhaled corticosteroids in clinically stabl e asthmatic patients, Design Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inha led corticosteroids dose decreases occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or m atching placebo once daily at bedtime for up to 12 weeks. Setting 23 academic asthma centres in United States, Canada, and Europe. Participants 226 clinically stable patients with chronic asthma receiving h igh doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo). Interventions Every 2 weeks, the inhaled corticosteroids dose was tapered, maintained, or increased (rescue) based on a standardised clinical score. Main outcome measures Last tolerated dose of inhaled corticosteroids, Results Compared with placebo, montelukast allowed significant (P = 0.046) reduction in the inhaled corticosteroid dose (montelukast 47% v placebo 30% ; least square mean difference 17.6%, 95% confidence interval 0.3 to 34.8). Fewer patients on montelukast (18 (16%) v 34 (30%) placebo, P = 0.01) requ ired discontinuation because of failed rescue. Conclusions Montelukast reduces the need for inhaled corticosteroids among patients requiring moderate to high doses of corticosteroid to maintain ast hma control.